Fulvestrant for the treatment of advanced breast cancer
Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone rece...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Published: |
Taylor & Francis
2018
|
| Online Access: | https://eprints.nottingham.ac.uk/52665/ |
| _version_ | 1848798780562866176 |
|---|---|
| author | Blackburn, Sophie A. Parks, Ruth M. Cheung, Kwok-Leung |
| author_facet | Blackburn, Sophie A. Parks, Ruth M. Cheung, Kwok-Leung |
| author_sort | Blackburn, Sophie A. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy.
Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment.
Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone. |
| first_indexed | 2025-11-14T20:25:13Z |
| format | Article |
| id | nottingham-52665 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:25:13Z |
| publishDate | 2018 |
| publisher | Taylor & Francis |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-526652020-05-04T19:36:36Z https://eprints.nottingham.ac.uk/52665/ Fulvestrant for the treatment of advanced breast cancer Blackburn, Sophie A. Parks, Ruth M. Cheung, Kwok-Leung Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy. Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment. Expert commentary: Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone. Taylor & Francis 2018-05-15 Article PeerReviewed Blackburn, Sophie A., Parks, Ruth M. and Cheung, Kwok-Leung (2018) Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18 (7). pp. 619-628. ISSN 1473-7140 https://www.tandfonline.com/doi/abs/10.1080/14737140.2018.1473038 doi:10.1080/14737140.2018.1473038 doi:10.1080/14737140.2018.1473038 |
| spellingShingle | Blackburn, Sophie A. Parks, Ruth M. Cheung, Kwok-Leung Fulvestrant for the treatment of advanced breast cancer |
| title | Fulvestrant for the treatment of advanced breast cancer |
| title_full | Fulvestrant for the treatment of advanced breast cancer |
| title_fullStr | Fulvestrant for the treatment of advanced breast cancer |
| title_full_unstemmed | Fulvestrant for the treatment of advanced breast cancer |
| title_short | Fulvestrant for the treatment of advanced breast cancer |
| title_sort | fulvestrant for the treatment of advanced breast cancer |
| url | https://eprints.nottingham.ac.uk/52665/ https://eprints.nottingham.ac.uk/52665/ https://eprints.nottingham.ac.uk/52665/ |